Corbus Pharmaceuticals (NASDAQ:CRBP) CFO Sells 12,000 Shares of Stock

Posted by Brian Himes on Aug 10th, 2026

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP – Get Free Report) CFO Sean Moran sold 12,000 shares of Corbus Pharmaceuticals stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $10.08, for a total transaction of $120,960.00. Following the completion of the transaction, the chief financial officer owned 84,694 shares of the company’s stock, valued at $853,715.52. This trade represents a 12.41% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Corbus Pharmaceuticals Trading Down 7.0%

NASDAQ CRBP traded down $0.71 during trading hours on Monday, reaching $9.46. 335,692 shares of the company’s stock were exchanged, compared to its average volume of 327,211. The firm has a fifty day moving average of $8.72 and a 200-day moving average of $9.05. Corbus Pharmaceuticals Holdings, Inc. has a one year low of $7.12 and a one year high of $20.56. The stock has a market cap of $175.29 million, a PE ratio of -1.53 and a beta of 2.59.

Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.26) by ($0.55). As a group, research analysts forecast that Corbus Pharmaceuticals Holdings, Inc. will post -4.87 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. HC Wainwright reduced their price target on shares of Corbus Pharmaceuticals from $40.00 to $35.00 and set a “buy” rating on the stock in a research report on Friday. Guggenheim restated a “buy” rating on shares of Corbus Pharmaceuticals in a research report on Tuesday, May 26th. Mizuho dropped their target price on shares of Corbus Pharmaceuticals from $44.00 to $34.00 and set an “outperform” rating for the company in a research note on Tuesday, June 23rd. Jefferies Financial Group reduced their target price on shares of Corbus Pharmaceuticals from $36.00 to $33.00 and set a “buy” rating on the stock in a research report on Tuesday, May 12th. Finally, Wedbush decreased their price target on shares of Corbus Pharmaceuticals from $38.00 to $30.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 27th. Eight investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $41.12.

Check Out Our Latest Analysis on CRBP

Hedge Funds Weigh In On Corbus Pharmaceuticals

Several large investors have recently made changes to their positions in CRBP. AQR Capital Management LLC acquired a new stake in Corbus Pharmaceuticals in the first quarter worth about $573,000. Marshall Wace LLP bought a new position in shares of Corbus Pharmaceuticals in the 2nd quarter valued at about $137,000. Bank of America Corp DE boosted its stake in shares of Corbus Pharmaceuticals by 333.6% in the 2nd quarter. Bank of America Corp DE now owns 71,893 shares of the biopharmaceutical company’s stock valued at $496,000 after purchasing an additional 55,314 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Corbus Pharmaceuticals by 2.1% during the 3rd quarter. Vanguard Group Inc. now owns 612,030 shares of the biopharmaceutical company’s stock worth $7,742,000 after buying an additional 12,535 shares during the period. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Corbus Pharmaceuticals during the 3rd quarter worth approximately $129,000. Institutional investors and hedge funds own 64.64% of the company’s stock.

Corbus Pharmaceuticals Company Profile

(Get Free Report)

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.